MajesTEC-4

About this trial

This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.

Patient Profile

Patients with newly diagnosed multiple myeloma

Where’s this trial being run?

Beaumont Hospital, University Hospital Limerick, and University Hospital Galway

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

Print this page

For more detailed information

Click Here

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Questions

---

Summary Data

Name:	MajesTEC-4
Number:	23-21
Full Title:	Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)

Principal Investigator:	Dr Janusz Krawczyk
Type:	Industry Sponsored
Sponsor:	Janssen
Recruitment Started:	Global: 08-Sep-2022 Ireland:

Global Recruitment Target:	Approx. 1500 patients
Ireland Recruitment Target:	17 patients